Singapore, Singapore--(Newsfile Corp. - June 20, 2016) - Zecotek Photonics Inc. (TSXV: ZMS) (FSE: W1I), a developer of
leading-edge photonics technologies for medical, industrial and scientific markets, today announced that the Company has closed on
the second tranche of the private placement, previously announced on May 9, 2016, by selling 2,989,330 units of the Company at a
price of $0.30 per unit for gross proceeds of $896,799. The Company sold an aggregate of 5,249,330 units at a price of $0.30 for
total gross proceeds of $1,574,799.
Each unit of the Company consists of one common share and one common share purchase warrant. Each warrant of the second tranche
entitles the holder to acquire one common share at an exercise price of $0.43 per common share at any time on or before June 20,
2018.
The Company paid finder's fees on the second tranche consisting of cash fees totalling $60,676 and issued 310,986 finder's
warrants. Each finder's warrant entitles the Warrantholder to acquire one unit (the "Unit") at a price of Cdn$0.30 per Unit. Each
Unit consists of one Common Share in the capital of the Company and one half of a share purchase warrant (the "Unit Warrant"). Each
whole Unit Warrant shall entitle the Warrantholder to acquire one Common Share at a price of Cdn$0.43 per Common Share until June
20, 2018.
All securities issued for the second tranche are subject to a four-month hold period expiring on October 20, 2016.
Net proceeds from the funds raised will be used to complete the transfer of technology for the purpose of immediate
commercialization, strengthen and maintain patents of the Company's IP portfolio, and used for purchase order financings and
general working capital purposes. Pursuant to the financing, the Company may pay a finder's fee. All shares and warrants are
subject to a four-month hold period.
About Zecotek
Zecotek Photonics Inc (TSXV: ZMS) (FSE: W1I) is a photonics technology company developing high-performance scintillation crystals,
photo detectors, positron emission tomography scanning technologies, 3D auto-stereoscopic displays, 3D metal printing, and lasers
for applications in medical, high-tech and industrial sectors. Founded in 2004, Zecotek operates three divisions: Imaging
Systems, Optronics Systems and 3D Display Systems with labs located in Canada, Korea, Russia, Singapore and U.S.A. The management
team is focused on building shareholder value by commercializing over 50 patented and patent pending novel photonic technologies
directly and through strategic alliances, the European Organization for Nuclear Research (Switzerland), Beijing Opto-Electronics
Technology Co. Ltd. (China), NuCare Medical Systems (South Korea), the University of Washington (United States), and National
NanoFab Center (South Korea). For more information visit www.zecotek.com and follow @zecotek
on Twitter.
This press release may contain forward-looking statements that are based on management's expectations, estimates, projections
and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are
difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.
For Additional Information Please Contact:
Zecotek Photonics Inc.
Michael Minder
T: (604) 783-8291
ir@zecotek.com
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or accuracy of the content of this news release. If you would like to
receive news from Zecotek in the future please visit the corporate website at www.zecotek.com.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.